TNXP - Tonix Pharma Debt to Book Capitalization Ratio

Tonix Pharmaceuticals (TNXP) is positioned as a versatile biopharmaceutical brand developing methods to combat infections and pain syndromes, with the current indicator standing at 0.01. This price chart illustrates the price action of the asset, whose future revenues rely on the commercialization of Tonmya for the therapy of PTSD and fibromyalgia. Operational activities are protected within the US domestic circuit, rendering the company immune to global political conflicts.

This indicator measures financial leverage by comparing total liabilities to equity to assess the business's resilience to bankruptcy. By analyzing the debt-to-capitalization ratio on the GURU.Markets balance sheet, an investor can see how Tonix Pharmaceuticals (TNXP) balances debt and government grants in the absence of mergers and an organic asset protection strategy.